A Randomized, Double- Blind, Placebo- Controlled, Multi- Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non- Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms ABCSG18
- Sponsors Amgen
- 05 Jun 2018 Results assessing the impact of adjuvant denosumab on disease-free survival presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 Aug 2016 Planned End Date changed from 1 Oct 2019 to 1 Jul 2020.
- 12 Dec 2015 Results (n=3425) presented at the 38th Annual San Antonio Breast Cancer Symposium